CLDI logo

Calidi Biotherapeutics (CLDI) Company Overview

Profile

Full Name:

Calidi Biotherapeutics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

November 1, 2021

Indexes:

Not included

Description:

Calidi Biotherapeutics (CLDI) focuses on developing innovative cancer treatments using oncolytic viruses. Their approach aims to target and destroy cancer cells while sparing healthy tissue, offering potential new therapies for patients. The company combines advanced science with a commitment to improving cancer care.

Events Calendar

Earnings

Next earnings date:

Mar 14, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Mar 15, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Jul 15, 2024

Analyst ratings

Recent major analysts updates

Jun 27, 24 Ladenburg Thalmann
Buy
May 15, 24 Baird
Outperform
Mar 21, 24 HC Wainwright & Co.
Buy
Mar 21, 24 Baird
Outperform
Nov 22, 23 HC Wainwright & Co.
Buy
Oct 9, 23 Baird
Outperform

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on February 5
Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on February 5
Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on February 5
CLDI
globenewswire.comJanuary 29, 2025

SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, is pleased to invite investors to a webinar on February 5, 2025, at 4:15 p.m. ET.

Calidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase Agreement
Calidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase Agreement
Calidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase Agreement
CLDI
globenewswire.comJanuary 28, 2025

SAN DIEGO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that its ending cash balance at December 31, 2024 was approximately $9.6 million. Due to Calidi's bolstered cash balance and success in recent fundraising, including proceeds resulting from its At-The-Market Offering Agreement (“ATM”), Calidi terminated its Standby Equity Purchase Agreement (“SEPA”) with YA II PN, Ltd., an affiliate of Yorkville Advisors, effective January 23, 2025.

Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock
Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock
Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock
CLDI
globenewswire.comJanuary 10, 2025

SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the closing of its previously announced public offering of 5,000,000 shares of common stock at $0.85 per share for gross proceeds of approximately $4.25 million.

Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock
Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock
Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock
CLDI
globenewswire.comJanuary 10, 2025

SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced that it priced its public offering of 5,000,000 shares of common stock at a price of $0.85 per share.

Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock
Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock
Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock
CLDI
globenewswire.comNovember 15, 2024

SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the closing of its previously announced public offering of 4,437,869 shares of common stock at $1.69 per share for gross proceeds of approximately $7.5 million.

Calidi Biotherapeutics Announces Proposed Public Offering
Calidi Biotherapeutics Announces Proposed Public Offering
Calidi Biotherapeutics Announces Proposed Public Offering
CLDI
globenewswire.comNovember 13, 2024

SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof) in an public offering. All of the shares of common stock (and/or Pre-funded Warrants) are to be sold by the Company.

Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results
Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results
Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results
CLDI
globenewswire.comNovember 12, 2024

SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today reported its operating and financial results for the third quarter ended September 30, 2024, and reviewed recent business highlights.

Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement
Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement
Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement
CLDI
globenewswire.comOctober 23, 2024

SAN DIEGO, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 2,050,000 shares of the Company's common stock at a price of $1.00 per share of common stock in a registered direct offering.

NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS)
NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS)
NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS)
CLDI
globenewswire.comOctober 18, 2024

SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that the staff of NYSE Regulation has determined to commence proceedings to delist the warrants — ticker symbol CLDI WS — of Calidi Biotherapeutics, Inc. (the “Company”), each whole warrant exercisable for 1/10th of a share of common stock at an exercise price of $115.00 per whole share of common stock, from the NYSE American. Trading in the Company's warrants will be suspended immediately. Trading in the Company's common stock — ticker symbol CLDI — will continue on the NYSE American.

Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results
Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results
Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results
CLDI
globenewswire.comAugust 13, 2024

SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSEAM: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today reported its operating and financial results for the second quarter ended June 30, 2024, and reviewed recent business highlights.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the ticker symbol for Calidi Biotherapeutics?
  • Does Calidi Biotherapeutics pay dividends?
  • What sector is Calidi Biotherapeutics in?
  • What industry is Calidi Biotherapeutics in?
  • What country is Calidi Biotherapeutics based in?
  • When did Calidi Biotherapeutics go public?
  • Is Calidi Biotherapeutics in the S&P 500?
  • Is Calidi Biotherapeutics in the NASDAQ 100?
  • Is Calidi Biotherapeutics in the Dow Jones?
  • When was Calidi Biotherapeutics's last earnings report?
  • When does Calidi Biotherapeutics report earnings?
  • Should I buy Calidi Biotherapeutics stock now?

What is the ticker symbol for Calidi Biotherapeutics?

The ticker symbol for Calidi Biotherapeutics is NYSE American:CLDI

Does Calidi Biotherapeutics pay dividends?

No, Calidi Biotherapeutics does not pay dividends

What sector is Calidi Biotherapeutics in?

Calidi Biotherapeutics is in the Healthcare sector

What industry is Calidi Biotherapeutics in?

Calidi Biotherapeutics is in the Biotechnology industry

What country is Calidi Biotherapeutics based in?

Calidi Biotherapeutics is headquartered in United States

When did Calidi Biotherapeutics go public?

Calidi Biotherapeutics's initial public offering (IPO) was on November 1, 2021

Is Calidi Biotherapeutics in the S&P 500?

No, Calidi Biotherapeutics is not included in the S&P 500 index

Is Calidi Biotherapeutics in the NASDAQ 100?

No, Calidi Biotherapeutics is not included in the NASDAQ 100 index

Is Calidi Biotherapeutics in the Dow Jones?

No, Calidi Biotherapeutics is not included in the Dow Jones index

When was Calidi Biotherapeutics's last earnings report?

Calidi Biotherapeutics's most recent earnings report was on Nov 12, 2024

When does Calidi Biotherapeutics report earnings?

The next expected earnings date for Calidi Biotherapeutics is Mar 14, 2025

Should I buy Calidi Biotherapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions